Key clinical features, colitis scores and accumulation of CD11b+ Gr-1high neutrophils were more severe in recipients of anti-CTLA4 and anti-PD-1 combination treatment than single agent treatment, and changes in anti-PD-1 recipients were generally milder than in anti-CTLA4 monotherapy (Supplementary Fig. 3a–d). The gene discussed is ITGAM; the disease is colitis.